NO344366B1 - Anvendelse av et radiomerket anti-CD20-antistoff for fremstilling av et medikament for behandling av en pasient med B-celle-lymfom. - Google Patents

Anvendelse av et radiomerket anti-CD20-antistoff for fremstilling av et medikament for behandling av en pasient med B-celle-lymfom. Download PDF

Info

Publication number
NO344366B1
NO344366B1 NO20070763A NO20070763A NO344366B1 NO 344366 B1 NO344366 B1 NO 344366B1 NO 20070763 A NO20070763 A NO 20070763A NO 20070763 A NO20070763 A NO 20070763A NO 344366 B1 NO344366 B1 NO 344366B1
Authority
NO
Norway
Prior art keywords
antibody
use according
nhl
radiolabeled
treatment
Prior art date
Application number
NO20070763A
Other languages
English (en)
Norwegian (no)
Other versions
NO20070763L (no
Inventor
Werner Krause
Joachim Kalmus
Jens Kuhlmann
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34972426&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO344366(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO20070763L publication Critical patent/NO20070763L/no
Publication of NO344366B1 publication Critical patent/NO344366B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20070763A 2004-07-09 2007-02-08 Anvendelse av et radiomerket anti-CD20-antistoff for fremstilling av et medikament for behandling av en pasient med B-celle-lymfom. NO344366B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58641404P 2004-07-09 2004-07-09
PCT/EP2005/007213 WO2006005477A1 (en) 2004-07-09 2005-07-07 Combination therapywith radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma

Publications (2)

Publication Number Publication Date
NO20070763L NO20070763L (no) 2007-02-08
NO344366B1 true NO344366B1 (no) 2019-11-18

Family

ID=34972426

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070763A NO344366B1 (no) 2004-07-09 2007-02-08 Anvendelse av et radiomerket anti-CD20-antistoff for fremstilling av et medikament for behandling av en pasient med B-celle-lymfom.

Country Status (13)

Country Link
US (2) US20060029543A1 (https=)
EP (1) EP1765399A1 (https=)
JP (2) JP2008505148A (https=)
KR (1) KR101250127B1 (https=)
AU (1) AU2005261923B2 (https=)
BR (1) BRPI0513007A (https=)
CA (1) CA2568526C (https=)
IL (1) IL179636A (https=)
MX (1) MX2007000327A (https=)
NO (1) NO344366B1 (https=)
RU (1) RU2394596C2 (https=)
WO (1) WO2006005477A1 (https=)
ZA (1) ZA200701158B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8061104B2 (en) 2005-05-20 2011-11-22 Valinge Innovation Ab Mechanical locking system for floor panels
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Ｃｄ２０ 항체 및 이의 용도
US11055552B2 (en) * 2016-01-12 2021-07-06 Disney Enterprises, Inc. Systems and methods for detecting light signatures and performing actions in response thereto

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009160A1 (en) * 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744877B2 (en) * 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
DK0752248T3 (da) * 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
WO2000059473A1 (en) * 1999-04-01 2000-10-12 Inex Pharmaceuticals Corp. Compositions and methods for treating lymphoma
WO2001074388A1 (en) * 2000-03-31 2001-10-11 Idec Pharmaceuticals Corporation Combined use of anti-cytokine antibodies or antagonists and anti-cd20 for the treatment of b cell lymphoma
WO2003068821A2 (en) * 2002-02-14 2003-08-21 Immunomedics, Inc. Anti-cd20 antibodies and fusion proteins thereof and methods of use
EP1567863A4 (en) 2002-11-22 2007-10-03 Nuvelo Inc THERAPY AND DIAGNOSTIC PROCEDURES

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000009160A1 (en) * 1998-08-11 2000-02-24 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
US20030206903A1 (en) * 1998-08-11 2003-11-06 Idec Pharmaceuticals Corporation Combination therapies for B-cell lynphomas comprising administration of anti-CD20 antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BRILLO-LOPEZ ANTONIO J., «A model for the breadth and depth of clinical effect observed with rituximab and zevalin in NHL patients.» Blood, vol. 100, no. 11, 2002, page Abstract No. 4780, Dated: 01.01.0001 *

Also Published As

Publication number Publication date
AU2005261923A1 (en) 2006-01-19
RU2007104839A (ru) 2008-08-20
NO20070763L (no) 2007-02-08
IL179636A0 (en) 2007-05-15
BRPI0513007A (pt) 2008-04-22
RU2394596C2 (ru) 2010-07-20
US20060029543A1 (en) 2006-02-09
ZA200701158B (en) 2008-09-25
CA2568526C (en) 2015-11-03
EP1765399A1 (en) 2007-03-28
JP6034314B2 (ja) 2016-11-30
WO2006005477A1 (en) 2006-01-19
US20190112383A1 (en) 2019-04-18
AU2005261923B2 (en) 2010-11-18
JP2008505148A (ja) 2008-02-21
MX2007000327A (es) 2007-03-12
CA2568526A1 (en) 2006-01-19
KR20070042527A (ko) 2007-04-23
IL179636A (en) 2013-09-30
KR101250127B1 (ko) 2013-04-02
JP2014080429A (ja) 2014-05-08

Similar Documents

Publication Publication Date Title
TWI786044B (zh) 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
CA2926771C (en) Cancer treatment with combination of plinabulin and taxane
JP5340935B2 (ja) 抗ｃｓ１抗体に基づく組合せ療法を用いて多発性骨髄腫を処置する方法
US20190112383A1 (en) Treatment of b-cell lymphoma
BR112020014960A2 (pt) Composição e método para redução de trombocitopenia
JP2013521338A (ja) 小細胞肺癌を治療するための方法
CN118765285A (zh) 用于肝细胞癌的组合疗法
Cheng et al. Chronic oral etoposide and tamoxifen in the treatment of far‐advanced hepatocellular carcinoma
CN121548431A (zh) 包含偶联物的药物组合的治疗方法和用途
Murray et al. Brief intensive chemotherapy for metastatic non-small-cell lung cancer: a phase II study of the weekly CODE regimen
Maringanti et al. MM-527 real world evaluation of teclistamab for the treatment of relapsed or refractory multiple myeloma (RRMM)
KR20240149434A (ko) 암을 치료하기 위한 체크포인트 저해제 및 종양용해 바이러스의 조합
US20250019441A1 (en) Treatment of cancer with anti-ilt2 antibodies
KR20220100006A (ko) 다중 표적 단백질 키나제 억제제의 용도
KR20260058844A (ko) 전립선암 치료를 위한 조합 요법
KR20200105825A (ko) 삼중 음성 유방암의 치료를 위한 ｐｄ－１ 항체 및 아파티닙의 조합 치료의 용도
WO2025141589A1 (en) Treatment of cancer with anti-ilt3 antibodies
TW202513554A (zh) 用於治療前列腺癌之組合療法
AU2022233742A1 (en) Use of oregovomab and bevacizumab, paclitaxel, carboplatin for treatment of brca-wild type platinum sensitive recurrent
JP2025126668A (ja) 人免疫グロブリンｇを有効成分として含有する、腎臓移植後の抗体関連型拒絶反応の治療剤
Ershler Fludarabine/Rituximab for Relapsed Hairy Cell Leukemia: Canadian Experience
Al-Shamahi American Society of Clinical Oncology-53rd Annual Meeting. Chicago, Illinois, USA-June 2-6, 2017
Kwong Rituximab in the Management of Follicular Lymphoma
HK40002353A (en) Methods of treating skin cancer by administering a pd-1 inhibitor
HK1226957A1 (en) Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab